Drugs / Ev.FV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07230223 | Jan 2024 → Dec 2025 overdue | epidermolysis bullosa dystrophica | Isfahan University of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ev.FV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230223 ↗ |
| Modality | Other / unclassified | “Extracellular vesicles and engineered EVs as messenger carriers” NCT07230223 ↗ |
| Route | Intravenous | “Ev.FV 1.0 x 1011 par/ml, IV, Total of 6 doses every 2weeks” NCT07230223 ↗ |